The landscape of American wellness and regenerative medicine is undergoing a significant transformation. Following a regulatory tightening in late 2023 that moved 19 popular peptides to the FDA's Category 2 list, recent comments by Department of Health and Human Services Secretary Robert F. Kennedy Jr. have signaled a potential reversal. Social media immediately filled with claims that 14 peptides are returning to Category 1 status.
For peptide clinic owners and compounding pharmacy operators, this news is highly anticipated. However, the gap between political commentary and formal regulatory change is wide. Understanding what has actually changed, what remains restricted, and how this affects your payment processing infrastructure is critical for protecting your business.
What RFK Jr. Actually Said, and What the Record Shows
During a February 2026 appearance on the Joe Rogan Experience, Secretary Kennedy criticized aspects of FDA oversight and discussed the need for reform regarding patient access to emerging therapies.
His remarks reflected a broader view that the federal government should reconsider certain regulatory approaches to wellness products. He did not issue any binding regulatory action.
As of March 2026, no peptide has been formally removed from Category 2 of the Section 503A bulk drug substances list. No Federal Register notice has been issued. No statute has been amended.[1] The Secretary of HHS can direct agency priorities and encourage enforcement discretion, but he cannot unilaterally bypass the Administrative Procedure Act to legalize peptide compounding overnight.
Political commentary and formal regulatory action are not the same thing. Enforcement discretion lowers enforcement pressure but does not eliminate legal risk or change the underlying statute.
How Peptides Are Classified Under Federal Law
Peptides intended for human use are regulated under the Federal Food, Drug, and Cosmetic Act. Traditional compounding pharmacies operate under Section 503A of that statute, which allows them to compound medications using bulk drug substances only if specific requirements are met.[4]
The FDA evaluates nominated bulk substances and places them into categories as part of its ongoing review process. Understanding these categories is essential for any clinic operator navigating this regulatory environment.
| Category | What It Means | Compounding Status |
|---|---|---|
| Category 1 | Evaluated and determined eligible for compounding; does not present significant safety risks | Eligible under 503A with valid prescription |
| Category 2 | FDA has identified potential significant safety risks or insufficient human safety data | Generally ineligible; compounding carries enforcement risk |
| Category 3 | Insufficient data to make a determination; under ongoing review | Status pending; proceed with caution |
Scroll to view full table →
Placement in Category 2 does not mean possession is criminal. It does mean that compounding and distributing the substance for human use carries regulatory risk and exposes the pharmacy to FDA enforcement action. The complete breakdown of FDA Category 1 vs. Category 2 peptides covers the full classification framework in detail.
Which 14 Peptides Are Expected to Return to Category 1
If formal reclassification occurs, approximately 14 peptides that were previously restricted are expected to return to Category 1 status. This reclassification would allow 503A compounding pharmacies to resume legal distribution to patients with valid prescriptions.
The substances most likely to be reclassified include BPC-157, a peptide studied in preclinical research for its potential effects on gut health and tissue repair; Thymosin Alpha-1, studied for its potential role in immune system modulation; and AOD-9604, a fragment of human growth hormone studied for its potential effects on fat metabolism. CJC-1295 and Ipamorelin, secretagogues that stimulate the natural production of growth hormone, are also expected to return, along with Selank and Semax, neuropeptides studied for potential neuroprotective and cognitive effects, and GHK-Cu, a copper peptide studied in dermatology research for potential wound-healing and skin-repair effects.[2]
Other peptides in this group include Thymosin Beta-4, Cathelicidin LL-37, Dihexa, Epitalon, Ibutamoren, Kisspeptin-10, KPV, and Mechano Growth Factor.
Not all peptides are expected to return. Melanotan II and GHRP-2 are expected to remain in Category 2 due to more concrete safety concerns or a lack of sufficient human clinical data.
What Reclassification Does NOT Mean for Your Clinic
The most common misconception circulating online is that moving from Category 2 to Category 1 makes these peptides legal to sell as supplements. This is entirely false.
Category 1 status simply means that licensed compounding pharmacies can produce these substances under physician prescription. They remain compounded medications that must be handled with professional care. They are not FDA-approved drugs, and they cannot be sold over the counter or marketed with claims that they treat, cure, or prevent disease.
Furthermore, the transition will take time. Even if enforcement discretion is applied immediately, formal rulemaking under the Administrative Procedure Act typically takes many months. Pharmacies must also source high-quality Active Pharmaceutical Ingredients that meet federal standards before they can resume production.
| Change Pathway | Timeline | Legal Certainty | What It Does |
|---|---|---|---|
| Enforcement Discretion | Weeks to months | Low (temporary) | Lowers enforcement pressure; does not change the law |
| Reclassification Review | Months or longer | Moderate | Improves regulatory posture; does not automatically authorize compounding |
| Formal Federal Register Removal | 1 to 2 years+ | High | Durable change; requires APA compliance and advisory input |
| Full FDA Drug Approval | Years | Highest | Permanent approval for a specific medical use; requires clinical trials |
Scroll to view full table →
How This Regulatory Shift Affects Your Payment Processing
Many clinic operators assume that if peptides return to Category 1, their payment processing problems will disappear. This is a dangerous strategic error.
Card networks like Visa and Mastercard classify merchants based on their own risk models, not just FDA categories.[5] The health and wellness sector, particularly businesses selling compounded medications or telehealth services, is inherently classified as high-risk due to regulatory complexity, prescription involvement, and elevated chargeback potential.
Even if the FDA formally reclassifies BPC-157 tomorrow, standard processors that rely on algorithmic underwriting will continue to flag and terminate peptide merchant accounts. Their models are designed to eliminate risk entirely, not to navigate the nuances of compounding pharmacy law.
The recent shutdown of major research peptide vendors highlights the ongoing financial infrastructure risk in this industry.[3] Increased visibility often leads to increased caution from standard payment processors and acquiring banks. The broader context of why this happens is covered in the guide to why standard processors terminate peptide merchant accounts.
Built for clinics that operate in regulated categories.
Direct underwriting. Manual review. No algorithmic shutdowns. Stable infrastructure regardless of where the rulemaking lands.
What Clinic Operators Should Do Right Now
The regulatory landscape for peptides is evolving, but the financial infrastructure requirements remain strict. Clinics that wait for "legalization" before setting up proper payment infrastructure are leaving their revenue vulnerable to sudden account freezes.
To protect your business during this transition period, you must secure a high-risk merchant account built specifically for health and wellness operators. The peptide clinic payment processing guide covers the full onboarding process in detail, including what documentation strengthens your application and how to structure your business for long-term stability.
We provide USA-based merchant accounts powered by institutional-grade infrastructure. We maintain direct BIN access and handle card network compliance registration directly on behalf of our merchants. We use true MCC codes, ensuring your business is classified correctly from day one.
LegitScript certification is not a prerequisite for working with us. Our underwriting team evaluates each merchant's compliance posture individually. We process what others refuse, providing the stability your clinic needs to operate confidently, regardless of how quickly the federal administrative process moves.
Frequently Asked Questions
No. Category 1 status means the FDA does not currently intend to take enforcement action against pharmacies that compound these substances. FDA approval is a separate process requiring multi-phase clinical trials for a specific medical use and can take years to complete.
No. These substances require a prescription from a licensed healthcare provider and must be dispensed by a licensed pharmacy. Category 1 reclassification does not create an over-the-counter pathway.
Standard processors use algorithmic underwriting that flags the entire health and wellness category as high-risk. They do not have the specialized underwriting teams required to evaluate compounding pharmacy compliance, so they terminate accounts to avoid potential card network fines.
It depends on your processor. Many standard processors require LegitScript certification as a condition of onboarding. Specialized high-risk processors evaluate each merchant individually and may have different requirements. Contact us directly to discuss your specific situation.
Formal rulemaking under the Administrative Procedure Act typically takes many months and may extend beyond a year. Enforcement discretion can be applied more quickly, but it does not change the underlying law and does not create a permanent safe harbor.